Genome Editing Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Genome Editing Market in 2025 is estimated at USD 10.7 billion. The global Market size surpassed USD 9.47 billion in 2024 and is projected to witness a CAGR of over 16.2%, crossing USD 66.69 billion revenue by 2037. North America is poised to achieve USD 23.34 billion by 2037, fueled by increase in population, research activity, and availability of health insurance covering cancer diagnoses.
The market's growth is primarily due to the high prevalence of cancer around the globe. In 2020, the World Health Organization reported that approximately 10 million people succumbed to cancer worldwide. The most common types of cancer that caused fatalities were lung cancer, which accounted for 1.8 million deaths, colon and rectal cancer with 916,000 deaths, liver cancer with 830,000 deaths, stomach cancer with 769,000 deaths, and breast cancer with 685,000 deaths. Furthermore, diseases like human papillomavirus (HPV) and hepatitis have been found to cause about 30% of cancer cases in low- and middle-income countries.
The market is growing due to advancements in gene editing tools, government funding, and an increase in genomics projects. The rise in cancer and genetic diseases and the development of CRISPR-based diagnostic tools for COVID-19 are also contributing. CRISPR-Cas9 dominates with 65% revenue share, expected to reach 70% by 2025. High device costs and ethical concerns hinder growth, but emerging markets and drug discovery opportunities hold promise.
Genome Editing Sector Market: Growth Drivers and Challenges
Growth Drivers
- Increasing Oncology Spending -The economic expenditure on cancer treatment and genome editing development is increasing year by year in various healthcare fields around the world. Global oncology spending in the year 2021 was found to be around USD 185 billion. For comparison, six years ago oncology spending was about USD 85 billion.
- Rise in Research Spending - the global market is expected to grow due to increased investment in research and development activities aimed at finding more effective solutions for genome editing such as Cancer Biomarkers. According to research reports, global spending on R&D has increased more than threefold in real terms since 2000, with the amount rising from roughly USD 680 billion to over USD 2.5 trillion in 2019.
- Prevalence of Cancer Worldwide -In the year 2019, 18 million new cancer cases and 10 million cancer deaths were observed worldwide. Population growth and aging worldwide alone are expected to result in 27.5 million new cancer cases and 16.3 million cancer deaths.
Challenges
- High Cost of Genome Editing Systems - Genome editing systems are specialized technologies used to precisely modify genetic material in living organisms. However, their high cost can hinder market growth.
- Lack of skilled professionals.
- The growing concern over risks and ethical issues associated with genome editing.
Genome Editing Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
16.2% |
|
Base Year Market Size (2024) |
USD 9.47 billion |
|
Forecast Year Market Size (2037) |
USD 66.69 billion |
|
Regional Scope |
|
Genome Editing Segmentation
Application (Cell Line Engineering, Genetic Engineering, Drug Discovery, Gene-modified Cell Therapy, Diagnostics)
Genetic engineering segment in the genome editing market is expected to garner a significant share in the year 2037. The growth of this segment can be attributed to advancements in gene editing technologies. Recent progress in gene editing technologies, such as CRISPR-Cas9, has significantly improved the accuracy and effectiveness of genetic engineering. As a result, new opportunities for gene therapy, drug development, and agricultural applications have emerged.
End Users (Academics & Government Institutes, Biotechnology & Pharma Companies, Hospitals)
Hospitals segment is estimated to gain the largest market share of about 42% in the year 2037. The healthcare industry is expanding rapidly, with a significant number of patients contributing to the growth of the sector. There has been a notable increase in the number of hospitals, with approximately 6,100 hospitals in the United States by 2022. Hospitals offer a wide range of medical care, and with genome editing emerging as a major treatment for many illnesses, the hospitals segment is expected to continue to grow.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
End Users |
|
|
Technology |
|
|
Delivery |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportGenome Editing Industry - Regional Synopsis
North American Market Forecast
The genome editing market in North America is expected to dominate over the forecast period accounting for 35% of the revenue share. The growth in the region is primarily due to an increase in population and research activity, as well as the availability of health insurance that covers various cancer diagnoses and related genome editing. Patients' ability to afford advanced treatments and the rising economic status in the region are expected to further drive market growth during the forecast period. In August 2022, personal income in the U.S. grew by 0.3% to reach USD 71.6 billion, while personal spending grew by 0.4% to reach USD 6.75 billion, according to the U.S. Bureau of Economic Analysis.
APAC Statistics
The Asia Pacific genome editing market is expected to hold a large share of about 24%. This is due to the region having the fastest ageing population in the world, with an estimated 1.3 billion geriatric population by 2050. The rise in cancer patients and deaths, along with funding for medical infrastructure, are also expected to contribute to market growth.
Top Featured Companies Dominating the Global Genome Editing Market
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck KGaA
- Horizon Discovery Ltd.
- Lonza Group Ltd.
- Twist Bioscience Corporation
- Akron Biotech.
- CRISPR Therapeutics
- Sangamo Therapeutics
- Editas MedicineIntellia Therapeutics, Inc.
In the News
- Merck acquired AmpTec, a Hamburg-based mRNA contract development and manufacturing organization (CDMO).
- Gibco CTS TrueCut Cas9 Protein enables genome editing for research and manufacturing, including CAR T-cell therapy.
Author Credits: Radhika Pawar
- Report ID: 4807
- Published Date: May 08, 2025
- Report Format: PDF, PPT
